NCT04030026View on ClinicalTrials.gov

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

NAL ER

Participants received NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID.

DRUG

Placebo

Participants received Placebo tablet (matching NAL ER ).

Trial Locations (11)

CB23 3RE

09, Cambridge

HU16 5JQ

08, Cottingham

DD1 9SY

17, Dundee

Unknown

13, Edinburgh

14, Oxford

NW1 2BU

04, London

SW3 6NP

01, London

M23 9LT

02, Manchester

NE1 4LP

10, Newcastle upon Tyne

NG5 1PB

06, Nottingham

SO16 6YD

03, Southampton

Sponsors

Lead Sponsor

Trevi Therapeutics

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Trevi Therapeutics

INDUSTRY